- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02171468
Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule in Healthy Japanese and Caucasian Male Subjects
June 20, 2014 updated by: Boehringer Ingelheim
Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule (110 mg and 150 mg b.i.d., 7 Days) in Healthy Japanese and Caucasian Male Subjects (Open Label Study)
To investigate and compare pharmacokinetics, safety and pharmacodynamics of dabigatran etexilate following oral administration of multiple doses (110 mg and 150 mg b.i.d., 7 days) in healthy male subjects between Japanese and Caucasians
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
Japanese or Caucasian healthy male subjects according to the following criteria:
Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate and body temperature), 12-lead electrocardiogram, clinical laboratory tests
- No finding of clinical relevance
- No evidence of a clinically relevant concomitant disease
- Caucasian subjects are from a well-defined Caucasian population, both parents of Caucasians, the subjects can understand the subject information for informed consent in English and the subjects have lived 8 or less than 8 years in Japan
- Age: ≥20 and ≤45 years
- Body mass index (BMI): ≥18.5 and ≤29.9 kg/m2
- Signed and dated written informed consent before admission to the trial site
Exclusion Criteria:
- Current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Subject can not use an adequate form of contraception from the time of the first dose on Day 1 up to end-of study examination
- Current diseases of the central nervous system (such as epilepsy), or psychiatric disorders or neurological disorders
- History of clinically significant orthostatic hypotension, clinically significant current or past fainting spells or blackouts
- Chronic or relevant acute infections
History of
- allergy/hypersensitivity (including drug allergy) which is deemed relevant to the safety assessment as judged by the investigator (excluding asymptomatic seasonal rhinitis/hay fever)
- any bleeding disorder including prolonged or habitual bleeding
- other hematologic diseases
- cerebral bleeding (e.g. after a car accident)
- concussions (head trauma resulting in injuring to brain) with or without loss of consciousness
- Intake of drugs with a long half-life (>24 hours) within at least 1 month or less than 10 half-lives, whichever is shorter, of the respective drug prior to administration or during the trial
- Use of aspirin (including over-the-counter medications), antipletelet agents like ticlopidine or dipyridamole, chronic administration of nonsteroidal antiinflammatory drugs , coumadin like anticoagulants, chronic use of corticosteroids, heparin or fibrinolytic agents within 28 days prior to administration up to end-of-study examination
- Participation in another trial with an investigational drug within 3 months prior to administration up to end-of-study examination
- Smoker (>10 cigarettes/day or inability to refrain from smoking during the trial)
- Alcohol abuse (more than 60 g/day; confirmed by interview)
- Drug abuse (confirmed by interview)
- Blood donation (more than 100 mL from 3 months prior to screening and any blood donation from screening up to end-of-study examination)
- Excessive physical activities (within 7 days prior to the first drug administration up to end-of-study examination)
- Any laboratory value outside the reference range that is of clinical relevance
- Known hypersensitivity to the investigational drug or its excipients
- Subject who was judged ineligible by the investigator or the sub-investigator
- History of any familial bleeding disorder
- Thrombocytes <15 x 10**4 /microL
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dabigatran high dose
|
|
Experimental: Dabigatran low dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)
Time Frame: up to 7 days
|
up to 7 days
|
Occurrence of adverse events
Time Frame: up to 10 days
|
up to 10 days
|
Changes in QT(c) intervals
Time Frame: up to 7 days
|
up to 7 days
|
Cmax,ss (maximum measured concentration of the analyte in plasma at steady state)
Time Frame: up to 7 days
|
up to 7 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration)
Time Frame: up to 7 days
|
up to 7 days
|
Cmax (maximum measured concentration)
Time Frame: day 1
|
day 1
|
tmax (time from dosing to maximum measured concentration)
Time Frame: day 1
|
day 1
|
AUCτ,1 (area under the concentration-time curve over a uniform dosing interval τ after administration of single dose on Day 1)
Time Frame: day 1
|
day 1
|
tmax,ss (time from last dosing to maximum concentration at steady state)
Time Frame: up to 7 days
|
up to 7 days
|
Cmin,ss (minimum concentration at steady state over a uniform dosing interval τ)
Time Frame: up to 7 days
|
up to 7 days
|
λz,ss (terminal rate constant at steady state)
Time Frame: up to 7 days
|
up to 7 days
|
t1/2,ss (terminal half-life at steady state)
Time Frame: up to 7 days
|
up to 7 days
|
MRTpo,ss (mean residence time in the body at steady state after oral administration)
Time Frame: up to 7 days
|
up to 7 days
|
CL/F,ss (apparent clearance in the plasma at steady state after extravascular multiple dose administration)
Time Frame: up to 7 days
|
up to 7 days
|
RA,Cmax,13 (accumulation ratio calculated as Cmax,ss/Cmax)
Time Frame: up to 7 days
|
up to 7 days
|
RA,AUC,13 (accumulation ratio calculated as AUCτ,ss/AUCτ,1)
Time Frame: up to 7 days
|
up to 7 days
|
area under the curve for activated partial thromboplastin time (aPTT)
Time Frame: 0 - 12 hours after adminstration on day 1 and day 7
|
0 - 12 hours after adminstration on day 1 and day 7
|
area under the curve for ecarin clotting time (ECT)
Time Frame: 0 - 12 hours after adminstration on day 1 and day 7
|
0 - 12 hours after adminstration on day 1 and day 7
|
comparison of trough concentrations
Time Frame: after doses 3, 5, 7, 9, 11 and 13
|
after doses 3, 5, 7, 9, 11 and 13
|
comparison of trough concentrations morning versus evening
Time Frame: after doses 9, 10, 11, 12, 13
|
after doses 9, 10, 11, 12, 13
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2006
Primary Completion (Actual)
July 1, 2006
Study Registration Dates
First Submitted
June 20, 2014
First Submitted That Met QC Criteria
June 20, 2014
First Posted (Estimate)
June 24, 2014
Study Record Updates
Last Update Posted (Estimate)
June 24, 2014
Last Update Submitted That Met QC Criteria
June 20, 2014
Last Verified
June 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1160.61
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Dabigatran high dose
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimTerminatedHeart Valve DiseasesBelgium, Canada, Czech Republic, Denmark, France, Germany, Netherlands, Norway, Poland, Sweden
-
Boehringer IngelheimTerminatedThromboembolism | Heart Valve ProsthesisBelgium, Canada, Czech Republic, Denmark, France, Germany, Netherlands, Norway, Poland
-
Boehringer IngelheimCompletedThromboembolism | Arthroplasty, Replacement, KneeUnited States, Canada, Mexico, United Kingdom
-
Boehringer IngelheimCompletedAtrial FibrillationUnited States, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Korea, Republic of, Malaysia, Netherlands, Norway, Phili... and more
-
Beijing Northland Biotech. Co., Ltd.CompletedAcute Myocardial InfarctionChina
-
National Institute of Diabetes and Digestive and...Washington University School of Medicine; University of Alabama at Birmingham; Icahn School of Medicine at Mount Sinai and other collaboratorsCompletedEnd Stage Renal DiseaseUnited States
-
Boehringer IngelheimUppsala University; Population Health Research InstituteCompletedStroke | Atrial FibrillationUnited States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, N... and more